Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesBeginning Cash BalanceCash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

InMed Pharmaceuticals (INM) Cash from Operations: 2020-2025

Historic Cash from Operations for InMed Pharmaceuticals (INM) over the last 6 years, with Jun 2025 value amounting to -$7.8 million.

  • InMed Pharmaceuticals' Cash from Operations rose 12.00% to -$1.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$7.5 million, marking a year-over-year decrease of 13.70%. This contributed to the annual value of -$7.8 million for FY2025, which is 11.18% down from last year.
  • Latest data reveals that InMed Pharmaceuticals reported Cash from Operations of -$7.8 million as of FY2025, which was down 11.18% from -$7.0 million recorded in FY2024.
  • InMed Pharmaceuticals' Cash from Operations' 5-year high stood at -$7.0 million during FY2024, with a 5-year trough of -$15.6 million in FY2022.
  • Moreover, its 3-year median value for Cash from Operations was -$7.3 million (2023), whereas its average is -$7.3 million.
  • In the last 5 years, InMed Pharmaceuticals' Cash from Operations crashed by 59.17% in 2022 and then surged by 53.26% in 2023.
  • Yearly analysis of 5 years shows InMed Pharmaceuticals' Cash from Operations stood at -$9.8 million in 2021, then tumbled by 59.17% to -$15.6 million in 2022, then skyrocketed by 53.26% to -$7.3 million in 2023, then rose by 4.08% to -$7.0 million in 2024, then dropped by 11.18% to -$7.8 million in 2025.